利福昔明在消化疾病中的临床应用进展  

Clinical application progress of Rifaximin in the treatment of digestive diseases

作　　者：崔东来[1] 陈卫[2] 姚希贤[1] 

机构地区：[1]河北医科大学第二医院消化内科,河北省石家庄市050000 [2]河北体育学院医院内科,河北省石家庄市050041

出　　处：《世界华人消化杂志》2007年第13期1457-1462,共6页World Chinese Journal of Digestology

摘　　要：利福昔明(Rifaximin)是利福霉素衍生物,对多种革兰阳性、革兰阴性需氧菌和厌氧菌均有高度抗菌活性,是治疗大肠埃希菌所致旅游者腹泻的一种新药.口服不易被肠道吸收,在肠道内有较高浓度,全身不良反应轻微是其特点.近年来利福昔明在肝性脑病、肠内胀气及肠道气体相关性疾病、憩室病、肠内细菌过度生长、炎症性肠病(IBD)以及幽门螺杆菌感染(H pylori)的根除等疾病治疗中应用日趋广泛并取得了较好疗效.Rifaximin, a derivative of rifamycin, has high antibacterial activity on various kinds of Grampositive and -negative aerobes and anaerobes, and it is a new drug in the treatment of giardiasis Rifaximin is not easy to be absorbed after oral administration, and mild systemic adverse reaction is the main characteristic. Recently, Rifaximin has been widely and effectively used in the therapy of many diseases related to intestinal bacterial infection such as hepatic encephalopathy, diverticular disease, overgrowth of intestinal bacteria, inflammatory bowel disease （IBD） and H pylori infection. The above advances were reviewed in the present article.

关 键 词：利福昔明 憩室病 肠内细菌过度生长 炎症性肠病 幽门螺杆菌 

分 类 号：R57[医药卫生—消化系统]